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Abstract
Background: neuropeptide S (NPS) and its receptor NPSR1 act along the hypothalamic-pituitary-adrenal axis to modulate
anxiety, fear responses, nociception and inflammation. The importance of the NPS-NPSR1 signaling pathway is highlighted
by the observation that, in humans, NPSR1 polymorphism associates with asthma, inflammatory bowel disease, rheumatoid
arthritis, panic disorders, and intermediate phenotypes of functional gastrointestinal disorders. Because of the genetic
complexity at the NPSR1 locus, however, true causative variations remain to be identified, together with their specific effects
on receptor expression or function. To gain insight into the mechanisms leading to NPSR1 disease-predisposing effects, we
performed a thorough functional characterization of all NPSR1 promoter and coding SNPs commonly occurring in
Caucasians (minor allele frequency .0.02).
Principal Findings: we identified one promoter SNP (rs2530547 [2103]) that significantly affects luciferase expression in
gene reporter assays and NPSR1 mRNA levels in human leukocytes. We also detected quantitative differences in NPS-
induced genome-wide transcriptional profiles and CRE-dependent luciferase activities associated with three NPSR1 non-
synonymous SNPs (rs324981 [Ile107Asn], rs34705969 [Cys197Phe], rs727162 [Arg241Ser]), with a coding variant exhibiting a
loss-of-function phenotype (197Phe). Potential mechanistic explanations were sought with molecular modelling and
bioinformatics, and a pilot study of 2230 IBD cases and controls provided initial support to the hypothesis that different cis-
combinations of these functional SNPs variably affect disease risk.
Significance: these findings represent a first step to decipher NPSR1 locus complexity and its impact on several human
conditions NPS antagonists have been recently described, and our results are of potential pharmacogenetic relevance.
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Introduction
The latest member to be discovered in the family of
neuropeptides is Neuropeptide S (NPS), characterized by the N-
terminal amino acid sequence Ser-Phe-Arg-Asn-Gly-Val-Gly,
which is identical in all animal species and represents the bioactive
portion of the molecule.[1] NPS selectively binds and activates its
receptor NPSR1 (neuropeptide S receptor, also known as GPR154
or G protein-coupled receptor for asthma susceptibility, GPRA), a
7-transmembrane G protein-coupled receptor (GPCR) that can
induce intracellular signalling via mobilization of calcium, increase
in cyclic adenosine monophospate (cAMP) levels, and the mitogen-
activated protein kinase (MAPK) pathway.[2] NPS and NPSR1
are mainly expressed in specific regions of the brain such as the
amygdala, the hypothalamic nucleus and the hippocampus and,
from studies in rodents, they appear to modulate several biological
functions including anxiety, locomotion, arousal, food intake, fear
memory and drug addiction.[3–8] In addition, recent studies from
our group have shown i) a direct effect of NPS on macrophage
adherence, migration and phagocytosis of bacteria,[9] ii) the
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transcriptional induction of proinflammatory cytokines (interleukin
8 [IL8] and substance P [SP]) upon NPS stimulation of epithelial
cells stably transfected with NPSR1 cDNA[10] and iii) increased
levels of NPSR1 mRNA in activated leukocytes, in lipopolysac-
charide (LPS)-stimulated peripheral blood mononuclear cells
(PBMCs), and in inflamed tissues from patients suffering from
asthma and inflammatory bowel disease (IBD).[9,11–13] A role for
the NPS-NPSR1 system in the modulation of neuroendocrine and
immune functions along the hypothalamic-pituitary-adrenal
(HPA) axis has therefore been postulated, and efforts are underway
to develop NPSR1 agonists and antagonists that might be
exploited for pharmaceutical use.[1]
Genetic variation at the NPSR1 locus (MIM 608595) is
associated in humans with predisposition to inflammatory diseases
such as asthma (MIM 600807), inflammatory bowel disease (IBD
[MIM 266600]) and rheumatoid arthritis (RA [MIM 180300]),
intermediate phenotypes of functional gastrointestinal disorders,
and panic disorders (MIM 167870);[11,12,14–19] that is, in
several conditions where alterations of NPSR1 signalling proper-
ties or expression may have important pathogenetic consequences
by way of dysregulating immune- or neuroendocrine-related NPS-
NPSR1 system function(s). Although a disease-predisposing role
has been demonstrated for NPSR1 in several studies and in
different populations, there has been only partial overlap of
markers in previous investigations, and associations have been
mainly accounted for by haplotypes tagged by single nucleotide
polymorphisms (SNPs) with less distinct individual effect on disease
risk.[11,12,14–27] NPSR1 true causative variants remain to be
identified, together with their specific effects on NPSR1 expression
and/or function.
The NPSR1 gene spans 220 kb of genomic DNA on
chromosome 7p14, in a region where .1000 SNPs have been
detected through sequencing of individuals of different ethnicity.
While, in theory, each SNP is of potential functional relevance,
best candidates to play a causative role may be initially sought in
regulatory and coding regions of the gene. Hence, to increase the
likelihood of identifying such variants, we sought to characterize
common (minor allele frequency [MAF] $0.02, figure 1) NPSR1
promoter and coding polymorphisms for their impact on,
respectively, the transcriptional regulation of gene expression
and the signalling properties of the corresponding receptor.
Materials and Methods
Ethics statement
Ethical approval was obtained from the following local ethics
committees: Karolinska Insitutet, Stockholm, Sweden and O¨rebro
University Hospital, O¨rebro Sweden (for the genetic analyses
carried out on IBD patients and controls); Amedeo Avogadro
University, Novara, Italy (for the analysis of gene expression in
peripheral blood). Written informed consent was obtained from
Swedish IBD patients recruited at the Karolinska Institutet and
O¨rebro University Hospital, and from healthy volunteers recruited
at the Amedeo Avogadro University. Verbal informed consent was
obtained from healthy blood donors recruited at the Blood Bank of
the O¨rebro University Hospital. At arrival at the Blood Centre,
Figure 1. NPSR1 polymorphisms characterized in this study, and vector constructs used for their functional analysis. Top: NPSR1
common (minor allele frequency [MAF] .0.02) promoter and coding SNPs and their location in the gene region. Left: Chromosomal position, MAF,
and functional effect of NPSR1 SNPs (minor alleles in lower case). Right: Vectors used to functionally characterize NPSR1 promoter (top) and coding
(bottom) SNPs. For coding polymorphisms, a Myc-tagged version of each construct has also been produced for the experiments of
immunofluorescence and FACS analysis.
doi:10.1371/journal.pone.0029523.g001
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blood donors were provided with written information, verbally
informed about the study, and given the possibility to ask questions
about the study. If a blood donor verbally approved to participate
in the study, a blood sample was collected for the genetic analyses.
This procedure was approved by the local ethical committee of the
O¨rebro University Hospital, only age and sex of the blood donors
were recorded and there is no way to trace back identities of the
included individuals. Furthermore, the ethical committee ap-
proved that the consent was not recorded in the medical notes,
since the enrolment was anonymous.
Human material
The genetic analysis of NPSR1 functional polymorphisms was
carried out on 1525 IBD patients and 705 controls, from a large
cohort of Swedish individuals described in detail in previous
publications.[11,28–32] Briefly, 659 Crohn’s disease (CD) patients
(aged 48.9615.1 SD, 52.6% males), 866 ulcerative colitis (UC)
patients (aged 52.1616.3 SD, 56.7% males) and 705 healthy
controls (aged 44.8614.6 SD, 56.3% males) were recruited at the
Karolinska University Hospital, Stockholm, and at the O¨rebro
University Hospital, O¨rebro, Sweden, upon their written informed
consent to participate in the study. Diagnosis of IBD (CD or UC)
was based on standard clinical, endoscopic, radiologic and
histologic criteria. Control individuals were healthy blood donors
free of inflammatory disease, who provided verbal informed
consent to be anonymously enrolled in the study.
For the correlation of NPSR1 mRNA expression with
rs2530547 (2103) genotype, peripheral blood was obtained from
42 healthy volunteers (all white Caucasians, aged 30.266.6 SD,
40% males), recruited at Amedeo Avogadro University, Novara,
Italy, upon written informed consent.
Cloning and mutagenesis
NPSR1 promoter was amplified from genomic DNAwith primers
CTCGAGGTCCTAGGTAGAAGCTGAGGT (forward) and
AAGCTTGGCTCAGGCGGGGTTGAG (reverse), and cloned
into pGL3-Basic Firefly Luciferase reporter vector (Promega,
Madison, WI, USA) by using XhoI and HindIII restriction
enzymes. NPSR1 expression vectors (full-length cDNA and N-
terminal Myc-tagged full-length cDNA) have been previously
described.[13] Allelic variants of NPSR1 promoter and cDNA
vectors were produced by site-directed mutagenesis using the
QuickChange II Site DirectedMutagenesis kit (Stratagene, La Jolla,
CA, USA). The entire inserts of all clones were sequence-verified.
The specificity of each clone is reported in figure 1.
Cell culture and transfection
HEK293 (ATCC CRL-1573) kidney epithelial and Colo205
(ATCC CCL-222) colon carcinoma cell lines were cultured in
Minimal Essential Medium (MEM from Invitrogen, Carlsbad,
CA, USA) and RPMI 1640 (Gibco BRL, Gaithersburg, MD,
USA), respectively, supplemented with 10% foetal calf serum and
1% penicillin/streptomycin. Transfections were carried out with
FUGENE 6 and FUGENE 6 HD (Roche Diagnostics, Basel, CH)
respectively for HEK293 and Colo205, with 05–1 mg of total DNA
according to manufacturer’s instructions.
Luciferase assays
For the study of NPSR1 promoter SNPs, Colo205 cells were co-
transfected with 900 ng of NPSR1 promoter allelic constructs and
100 ng of pRL-TK Renilla Luciferase reporter vector (Promega,
Madison, WI, USA), and total cell lysates were prepared 24 h post
transfection. For pharmacokinetic studies, HEK293 cells were co-
transfected with 400 ng of NPSR1 cDNA expression vectors
specific for different coding variants and 50 ng each of cAMP
response element (CRE) Firefly Luciferase reporter vector and
CMV Renilla Luciferase reporter plasmid (purchased as pre-
formulated mix from SABiosciences, Frederick, MD, USA). The
day after transfection cells were stimulated for 6 h with NPS
(MedProbe, Oslo, Norway) at various concentrations (ranging 10
pM – 100 mM) before preparation of total cell lysates. In all
reporter assays, Luciferase activity was calculated using the Dual-
Luciferase Reporter Assay System (Promega) according to
manufacturer’s instructions, and a Microplate Reader Infinite
200 (Tecan, Ma¨nnedorf, CH). Experiments were done in
triplicate, and Firefly Luciferase activity expressed in arbitrary
units relative to the control vector, after normalization for
transfection efficiency based on values obtained for Renilla
Luciferase.
Immunofluorescence
HEK293 cells were transfected with N-terminal Myc-tagged
NPSR1 cDNA expression vectors corresponding to different
coding variants. Twenty-four hours post transfection cells were
fixed by incubation in 4% paraformaldehyde (in PBS) for 8–
10 min at room temperature. The coverslips were blocked and
primary rabbit anti-Myc tag antibody (Abcam, Cambridge, UK)
was diluted in blocking buffer and incubated with the cells for 1–
3 h. For the secondary antibody staining, Texas Red conjugated
donkey anti-rabbit serum (Jackson Immunoresearch, West Grove,
PA, USA) was diluted in blocking buffer containing 05 mg/ml
Hoechst 33258 (Invitrogen) for identification of cell nuclei.
Washed coverslips were then mounted in vinol mounting medium
and images were captured using a Leitz DM RB fluorescent
microscope Images were processed and compiled using Adobe
Photoshop.
Fluorescence-activated cell sorting (FACS) analysis
HEK293 cells were co-transfected with N-terminal Myc-tagged
NPSR1 cDNA expression vectors corresponding to different
coding variants and the pmaxGFP expression vector carrying
green fluorescent protein cDNA (Amaxa, Cologne, Germany).
Twenty-four h post transfection cells were treated with EDTA
0.5 M and then stained with anti-Myc primary antibody (Abcam)
followed by Alexa Fluor 647 goat anti-rabbit IgG secondary
antibody (Invitrogen). The analysis was performed on GFP
positive cells.
Real-Time PCR analysis
Total RNA was extracted from peripheral blood with
commercially available kits (Qiagen, Hilden, Germany), and
cDNA synthesized from 1 mg of RNA with SuperScriptTM III
First-Strand Synthesis SuperMix for qRT-PCR Kit (Invitrogen)
according to manufacturer’s instructions. NPSR1 messenger RNA
(mRNA) expression levels were measured by performing quanti-
tative real-time PCR in an ABI Prism 7500 Fast Sequence
Detection System (Applied Biosystems, Foster City, CA, USA)
with SYBRGreen mix according to the manufacturer’s instruc-
tions. Real-time PCR reactions were performed in triplicate on
each sample with primers CCCCCTCATCTACTGTGTCTT-
CA (forward) and TCTCTCCCGGAACGTCATTCT (reverse)
for NPSR1, and CCACATCGCTCAGACACCAT (forward) and
GCGCCCAATACGACCAAAT (reverse) for glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), which was used as internal
endogenous control. After normalization to GAPDH, NPSR1
mRNA expression levels in each sample were determined by the
NPSR1 Polymorphism and Disease
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comparative CT method of relative quantification, and expressed
in arbitrary units relative to a randomly chosen reference sample.
Microarray sample preparation and hybridizations
HEK293 cells were transfected with NPSR1 expression vectors
specific for each coding variant and with an empty (control) vector,
all in duplicate. Twenty-four h after transfection cells were
stimulated with 1 mM NPS (final concentration) for 6 h and total
RNA was purified with standard kits (Qiagen). RNA concentration
and quality were measured with Agilent 2100 Bioanalyzer (Agilent
Technologies, DE, USA), and a total of 8 mg of RNA from each
sample was used for target cDNA synthesis according to the
Affymetrix protocol. A total of 12 hybridizations (corresponding to
duplicate transfections for 1 control vector and 5 NPSR1 plasmids)
were performed on HGU133plus2 arrays (Affymetrix, Santa
Clara, CA, USA), which were scanned with a GeneChip Scanner
3000 (Affymetrix) according to manufacturer’s instructions and
protocols for gene expression technology.
Genotyping
Genomic DNA was isolated from peripheral blood with
commercially available kits (Qiagen). The SNPs rs2530547
(2103), rs324981 (Ile107Asn), rs34705969 (Cys197Phe), and
rs727162 (Arg241Ser) were genotyped in an ABI Prism 7500 Fast
Sequence Detection System (Applied Biosystems), respectively
with TaqManH SNP Genotyping Assays C___2959938_10,
C___2959781_10, C__58876042_10 and C___2277753_10, ac-
cording to manufacturer’s instructions.
Molecular modelling
The molecular model of NPSR1 was created using the FUGUE
Protein Modelling Server.[33] The crystal structure of the G
protein-coupled receptor bovine rhodopsin (pdb identity code
1U19) was used as a template for the modelling.[34] Figures were
created using the program PYMOL (http://www.pymol.org).
Bioinformatics and statistical analyses
In silico prediction of the NPSR1 promoter was obtained with
the ARTS software (http://www.fml.tuebingen.mpg.de/raetsch/
projects/arts). The TRANSFAC database was screened with
MatInspector 4.3 (http://www.genomatix.de)to search for tran-
scription factors (TFs) potentially binding to NPSR1 predicted
promoter. The effect of the SNP rs2530547 (2103) on TF binding
was evaluated with Match 1.0 (http://www.gene-regulation.com)
using a matrix similarity cut-off value of 0.8, while potential
variation in kinase-specific phosphorylation at NPSR1 residue 241
(SNP rs727162) was predicted with NetPhosK (http://www.cbs.
dtu.dk/services/NetPhosK).
For microarray analysis, the quality of the chips was assessed
using the guidelines and the benchmarks from Affymetrix (http://
www.affymterix.com). The software package Simpleaffy V 2.20.0
(http://www.bioconductor.org) from the Bioconductor Repository
was used in order to estimate background, scale factors,
percentage of present probesets, and GAPDH and beta-Actin
expression levels. The array passed all standard quality control
checks. Normalization of the microarray was done using the
package Affy 1.22 from the Bioconductor Repository. We used
only Perfect Match probes, invariant set, no background
subtraction and the Li-Wong summary method.[35] The differ-
ential expression of genes/probesets was assessed using the
hierarchical fitting method implemented in the software package
LIMMA 2.18.1 (http://www.bioconductor.org) with Benjamini &
Hochberg correction for multiple tests. We used a threshold p-
value of 0.05 (after correction) to record a gene/probeset as
differentially expressed, and only genes with fold changes .2 were
taken into account, according to Affymetrix guidelines. Enrich-
ment analysis of GO (Gene Ontology) terms was performed using
the package GOSTATS 2.10.0 (http://www.bioconductor.org).
Microarray data in compliance with the MIAME guidelines have
been deposited in the ArrayExpress database (http://www.ebi.ac.
uk/arrayexpress), with accession number E-MEXP-3226).
In the genetic analysis of NPSR1 functional SNPs, associations
between haplotypes and disease were tested using the algorithm
haplocc from the R package haplo.stats 1.4.4 (http://www.r-
project.org).[36] Haplotypes were reconstructed using an expec-
tation maximization algorithm with progressive loci insertion. A
generic log-additive model was used to test allelic effects for single
markers, a common (allele frequency .0.10) haplotype was
randomly chosen as baseline for OR calculations, and P values
were estimated by a chi square test over the deviance of the
regression. The Bonferroni correction method was adopted to take
into account the number of tested phenotypes (IBD, UC and CD),
and significance was set to P,0.017 (a=0.05/3).
A Mann-Whitney U test was used for the statistical analysis of
luciferase reporter assays performed with NPSR1 promoter
variants, and for the analysis of NPSR1 expression in blood from
healthy volunteers stratified according to genotype at the SNP
rs2530547 (2103). To evaluate the significance of allele-specific
differences (among NPSR1 coding variants) in the magnitude of
induction of differential gene expression following NPS stimula-
tion, a Wilcoxon matched-pairs signed-ranks test was performed
on genes showing fold change .4 in at least one transfection.
Results
Functional analysis of NPSR1 promoter polymorphisms
Bioinformatic analysis of the region upstream of NPSR1 coding
sequence resulted in the prediction of a unique promoter spanning
595 bp 59 of the translation initiation codon (ATG). Several
transcription factors known to modulate neurological functions
and inflammatory responses were predicted to bind to this region.
Among these, OCT1, Pdx1, NEUROD1, MEIS1, Ap1 and Myb
have been implicated in the regulation of expression of other
neuropeptides such as the neuropeptides Y and FF and the
vasoactive intestinal peptide (VIP). These results are graphically
depicted in figure S1. To verify whether the identified region
contains elements promoting transcription, we cloned the
corresponding genomic DNA fragment into a luciferase-reporter
vector, and used this construct to transiently transfect Colo205
cells, which are known to endogenously express NPSR1 mRNA[4].
As shown in figure S1, this plasmid gave rise to a 4-fold increase in
luciferase activity compared to the empty luciferase-reporter
vector, supporting the results obtained from the bioinformatic
prediction.
Four common SNPs (rs1963499, rs2168890, rs2530547 and
rs887020) map within the NPSR1 promoter, at positions 2565,
2553, 2103 and 243, respectively, from the ATG start codon
(figure 1 and figure S1). To assess their potential effect on NPSR1
transcription, we generated corresponding variants of the NPSR1
promoter plasmid (figure 1), and tested them in luciferase assays
performed with transient transfections of Colo205 cells. As shown
in figure 2A, while no relevant difference was detected for other
SNPs, substitution of a cytosine (C) with a thymidine (T) at the
2103 SNP site resulted in a significant reduction (62%) of
luciferase activity. To confirm and further extend this result, we
studied NPSR1 mRNA expression in peripheral blood from 42
healthy individuals with known rs2530547 genotype. As shown in
NPSR1 Polymorphism and Disease
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figure 2B, this analysis also indicated that this SNP may influence
transcriptional activity at the NPSR1 locus, since 2103 TT
homozygosity was significantly associated with reduced levels of
NPSR1 mRNA expression. Bioinformatic analysis of the DNA
sequence surrounding SNP rs2530547 predicted the 2103T allele
to disrupt a consensus sequence for the binding of ELK1 (Ets
domain-containing protein Elk-1), a DNA binding protein of the
ternary complex factor (TCF) subgroup of Ets transcription
factors.
Functional analysis of NPSR1 coding polymorphisms
Four coding polymorphisms occur in the NPSR1 gene with
MAF.0.02, namely rs324981 (Ile107Asn), rs34705969
(Cys197Phe), rs727162 (Arg241Ser) and rs6972158 (Gln344Arg)
(figure 1). To test their potential effect on receptor function, we
used site-directed mutagenesis to generate NPSR1 expression
vectors encoding receptor variants that differ at the corresponding
polymorphic amino acid residues (namely 107Asn, 197Phe,
241Ser and 344Arg; figure 1). Because of the lack of suitable
NPSR1-specific antibodies, we also produced Myc-tagged NPSR1
coding variants, which were uniquely used in receptor expression
studies (although they also displayed NPS-induced signalling
capacities comparable to their untagged equivalents, data not
shown).
We first tested whether amino acid changes corresponding to
NPSR1 alleles at coding SNPs have an effect on receptor
expression. HEK293 epithelial cells were transiently transfected
with Myc-tagged NPSR1 expression vectors and analyzed in
immunofluorescence (IF). As shown in figure 3, no coding
polymorphism disrupted NPSR1 expression on the cell mem-
brane, since IF detection with an anti-Myc antibody gave rise to
positive surface staining for all NPSR1 variants. To quantify their
relative level of expression on the membrane, we then performed
FACS experiments, and measured mean fluorescence intensity
(MFI) in HEK293 cells transiently transfected with Myc-tagged
NPSR1 coding variants. In these experiments, and as previously
reported also by others,[37] the 107Asn clone resulted in a
significantly lower level of NPSR1 membrane expression, but no
relevant differences could be detected for other coding variants
(figure 3).
A whole-transcriptome analysis was carried out to evaluate the
potential impact of NPSR1 coding SNPs on receptor signalling
properties. HEK293 cells transiently transfected with different
NPSR1 coding variants were stimulated with NPS for 6 h, and
changes in gene expression downstream of NPS-NPSR1 signalling
were quantified with Affymetrix GeneChipH Human Genome
U133 Plus 2.0 arrays. As previously shown in HEK293 cells stably
expressing the receptor,[10] analysis of microarray data based on
Gene Ontology (GO) showed that NPSR1 signalling generally
induces gene expression and transcriptional activation linked to
nucleic acid metabolism, inflammatory responses and responses to
stress or external stimuli (figure S2). We then compared the
transcriptome profiles of different NPSR1 coding variants
(available in full as table S1). As shown in Table 1, although no
variant-specific pattern of gene expression was detected, the
magnitude of NPS-induced transcriptional changes was markedly
different for different NPSR1 coding variants. The most dramatic
effect was observed for the substitution of a Cys with Phe in
position 197 (pNPSR1-197Phe construct), which resulted in a loss-
of-function pattern of gene expression, and virtually absent
transcriptional induction of downstream genes (pNPSR1-
197Phe:pNPSR1 mean fold change ratio = 0.2660.18 SD,
P,1.681610210). In addition, pNPSR1-107Asn and pNPSR1-
241Ser coding constructs both gave rise to weaker changes in gene
expression compared to the reference pNPSR1 receptor vector
(pNPSR1-107Asn:pNPSR1 mean fold change ratio = 0.7560.16
Figure 2. Effect of NPSR1 promoter polymorphism on gene transcription. A) Colo205 cells were transiently transfected with NPSR1
promoter constructs as indicated, in triplicate experiments. Twenty-four hours after transfection luciferase activity was measured and expressed as
fold changes (+ SD) relative to the reference construct pNPSR1P. The substitution of a cytosine (C) with a thymidine (T) at position 2103 (SNP
rs2530547) resulted in significantly lower levels of luciferase activity (pNPSR1P-103T vs pNPSR1P, Mann-Whitney U test P = 0.004). B) Blood levels of
NPSR1 mRNA were detected with TaqMan NPSR1-specific Real-Time PCR assay in 42 healthy volunteers, and expressed in arbitrary units according to
genotype at position -103 of NPSR1 promoter (SNP rs2530547). Homozygosity for the T allele at this locus correlated with lower levels of NPSR1
mRNA (Mann-Whitney U test P = 0.009).
doi:10.1371/journal.pone.0029523.g002
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SD, P= 1.681610210, pNPSR1-241Ser:pNPSR1 mean fold
change ratio = 0.9360.08 SD, P= 3.47361026). In contrast,
The 344Arg change had no significant effect on receptor signalling
properties (pNPSR1-344Arg:pNPSR1 mean fold change ra-
tio = 0.9860.14 SD, P=0.399).
To confirm and extend these functional results, we compared
NPSR1 coding variants in another experimental setting, and
assessed their dose-response to NPS in a luciferase assay
dependent on the activation of a cAMP-response element
(CRE). HEK293 cells were transiently co-transfected with
different NPSR1 coding variants and a CRE-Luc plasmid, and
luciferase activity measured 6 h after stimulation with serial
dilutions of NPS. As shown in figure 4, most NPSR1 variants
induced dose-dependent activation of luciferase activity, while
pNPSR1-197Phe cells displayed complete lack of signalling
induction at all tested concentrations of NPS. Also in these
experimental conditions, NPSR1 coding variants showed quanti-
tative differences similar to those observed in the transcriptome
analysis, particularly at higher NPS concentrations, and the
pNPSR1-241Ser and pNPSR1-107Asn transfected cells exhibited
slightly and strongly reduced signalling properties, respectively,
when compared to cells transfected with the reference pNPSR1
construct (figure 4).
These functional experiments demonstrated that the three SNPs
rs324981 (Ile107Asn), rs34705969 (Cys197Phe), and rs727162
(Arg241Ser) appear to affect NPSR1 signalling properties. The
amino acid residues corresponding to these SNPs are all well
conserved in NPSR1 across different species (figure S3). A
molecular model of the NPSR1 protein was created based on its
sequence similarity to the previously published crystal structure of
the G protein-coupled receptor bovine rhodopsin (figure 5).
Analysis of the model suggested that the residues isoleucine at
position 107 (Ile107), cysteine at position 197 (Cys197), arginine at
position 241 (Arg241), and glutamine at position 344 (Gln344) are
localized on different sides of the transmembrane protein: Ile107 is
at the extracellular end of the H2 helix, Cys197 is at the bottom of
the second extracellular loop, Arg241 is positioned on a cytosolic
domain that links helices H5 and H6, while Gln344 is localized on
a short intra-cytosolic helical stretch at the end of the H8 helix
(figure 5A). These results are in accordance with a recent study
where the interactions of NSPR with several non-peptide
antagonists were modelled, and where a similar localization for
the residue107 on the terminal portion of the second transmem-
brane helix (H2) was reported.[38] Importantly, our model
indicated that the side chain of Cys197 forms a disulfide bridge
with the side chain of residue cysteine at position 121 (Cys121)
within the core of the NPS binding domain (figure 5B). Disruption
of the disulfide bridge through the substitution of Cys197 with a
phenylalanine would probably have a profound effect on the
overall conformation of the protein as well as the properties of the
NPS ligand-binding pocket, which may impact ligand affinity and
thus explain the observed loss-of-function phenotype of the
197Phe variant. While the structural relevance of residue 107 in
antagonist binding has already been addressed in a previous
Figure 3. Membrane expression of NPSR1 coding variants. Top: HEK293 cells were transiently transfected with Myc-tagged NPSR1 expression
vectors corresponding to different coding variants as indicated, and stained with anti-Myc antibody (red) and Hoechst 33258 (blue). Bottom: FACS
analysis of cell surface expression of NPSR1 coding variants HEK293 cells were co-transfected with GFP and either an empty vector (ctrl) or vectors
carrying Myc-tagged cDNAs for NPSR1 and all coding variants as indicated. After gating for GFP, anti-Myc mean fluorescence intensity (MIF) was
measured for each sample, and the results obtained in three independent experiments are reported in the graph. In these conditions, the expression
of the pNPSR1-107Asn variant was significantly lower (t test) than that of pNPSR1, taken as reference for this series of experiments.
doi:10.1371/journal.pone.0029523.g003
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study,[38] our model indicates that residue Arg241 is facing the
intracellular compartment, and bioinformatic analysis of the
surrounding sequence resulted in the prediction of consensus
protein kinase A and C (PKA and PKC) phosphorylation sites
overlapping with this position in the presence of a serine (figure
S3). Hence, the NPSR1 Ile107Asn, Cys197Phe and Arg241Ser
Table 1. Genes differentially expressed upon NPS stimulation.
Affy probe Gene pNPSR1 pNPSR1 pNPSR1 pNPSR1 pNPSR1
107Asn 197Phe 241Ser 344Arg
204637_at CGA +62.77 +36.23 21.01 +46.55 +70.01
202859_x_at IL8 a +32.43 +16.34 21.01 +30.47 +34.54
211143_x_at NR4A1 a +25.97 +18.04 +1.15 +22.35 +28.22
209774_x_at CXCL2 +17.94 +9.73 +1.08 +17.09 +15.99
205476_at CCL20 +16.18 +4.18 +1.00 +15.55 +20.22
206552_s_at TAC1 +15.73 +12.06 21.17 +12.77 +16.32
36711_at MAFF a +14.94 +12.22 +1.43 +15.30 +13.90
227099_s_at LOC387763 +14.67 +10.59 +1.00 +14.56 +15.71
204621_s_at NR4A2 a +10.30 +8.24 21.04 +9.47 +11.15
218541_s_at C8orf4 +9.63 +6.35 +1.22 +9.88 +10.56
227404_s_at EGR1 a +8.55 +5.11 +1.22 +7.68 +7.75
207978_s_at NR4A3 a +8.47 +5.37 21.03 +6.82 +8.75
207768_at EGR4 +8.30 +3.55 +1.10 +9.14 +9.28
219716_at APOL6 +7.22 +6.04 +3.61 +6.40 +4.86
202508_s_at SNAP25 +7.15 +6.85 +1.95 +6.80 +6.24
1561434_at C15orf45 +6.36 +5.94 +3.06 +6.42 +5.15
213321_at BCKDHB +6.30 +5.31 +2.83 +6.13 +4.49
204472_at GEM +6.19 +4.60 21.06 +5.38 +6.04
209189_at FOS +5.73 +3.94 21.01 +4.88 +5.80
202768_at FOSB +5.67 +3.50 +1.10 +4.71 +4.95
202014_at PPP1R15A a +5.49 +4.39 +1.75 +4.98 +4.47
210511_s_at INHBA +5.43 +3.66 21.01 +4.69 +5.09
223774_at SNHG12 a +5.34 +5.30 +3.68 +5.69 +4.20
229709_at ATP1B3 +5.29 +3.76 21.10 +3.77 +5.96
206115_at EGR3 +5.25 +3.10 +1.03 +5.52 +6.13
226164_x_at RIMKLB a +5.23 +5.22 +2.60 +5.32 +4.79
227140_at NA +5.09 +3.72 21.04 +3.95 +5.04
202644_s_at TNFAIP3 a +4.96 +3.81 +1.80 +4.87 +4.87
202672_s_at ATF3 a +4.69 +4.08 +1.61 +4.65 +4.27
225557_at CSRNP1 +4.55 +3.84 +1.32 +4.28 +4.18
204846_at CP +4.52 +4.38 +3.65 +4.66 +4.15
1559563_at NA +4.37 +3.74 +2.26 +3.90 +3.19
201473_at JUNB +4.34 +3.65 +1.72 +4.53 +4.52
228536_at PRMT10 +4.33 +4.00 +1.26 +3.72 +3.93
209277_at TFPI2 a +4.33 +2.59 21.07 +4.27 +5.57
210538_s_at BIRC3 +4.31 +3.85 +2.16 +4.25 +4.41
218880_at FOSL2 +4.14 +3.86 +1.25 +3.90 +3.42
226206_at MAFK +4.02 +3.43 +1.35 +3.97 +3.50
1559565_x_at NA +4.02 +3.37 +2.13 +3.67 +3.27
226099_at ELL2 +3.93 +3.61 +1.09 +3.93 +4.29
205239_at AREG +3.91 +2.61 +1.03 +3.64 +4.73
1555571_at IMMP2L +3.81 +3.89 +2.71 +4.10 +3.37
NOTE: Differential expression is reported for each gene (Affymetrix probeset) and each NPSR1 variant in fold changes (fc) relative to cells transfected with an empty
vector. Reported are genes for which a fc .4 has been detected in at least one transfection (+ denotes up-regulation, and - down-regulation).
aHighest fc values are reported for genes with significant results for multiple probesets.
doi:10.1371/journal.pone.0029523.t001
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coding polymorphisms may act through different mechanisms to
affect receptor function and signalling properties.
Pilot study of NPSR1 functional polymorphisms in IBD
Finally, in a preliminary analysis, we sought to test NPSR1
functionally relevant SNPs for their potential association with
disease. For this purpose, we genotyped the SNPs rs2530547
(2103), rs324981 (Ile107Asn), rs34705969 (Cys197Phe), and
rs727162 (Arg241Ser) in 1525 IBD cases, comprising 659 CD
patients and 866 UC patients, and 705 healthy controls from
Sweden. Based on our results, we reasoned that a coherent analysis
of NPSR1 impact on disease risk needs to be performed by taking
into account several functional polymorphisms at once, that is by
testing cis allele combinations corresponding to ‘‘functional
haplotypes’’. However, as expected, the rs34705969 SNP had a
very low minor allele frequency in our population (T=0.023),
where TT homozygous individuals were absent, and this
polymorphism therefore was not included in the association tests.
Figure 4. Pharmacological activity of NPSR1 coding variants. Dose-response curves of NPS stimulation, in HEK293 cells transiently co-
transfected with a CRE-luc plasmid and NPSR1 coding variants in triplicate, as indicated. One representative experiment is reported, where CRE-driven
luciferase activity is expressed in mean arbitrary units 6 SEM.
doi:10.1371/journal.pone.0029523.g004
Figure 5. Molecular model of NPSR1. A) The molecular model of NSPR1 indicates that residues Ile107, Cys197 and Agr 241 are localized at each
end of the transmembrane NSPR1 protein, while residue Cys197 is within the presumptive NPS-binding site. The model (side view) is oriented with
the extracellular matrix and the cytosolic compartment at the top and at the bottom, respectively. Each of the seven helices that compose the NPSR1
transmembrane core is indicated with a different color and annotated with H. The side chains of the four different residues are displayed as spheres.
B) View of the molecular model of NPSR1 seen from the extracyoplasmic domain. Residues Ile107, Cys197 and Cys121 are indicated as sticks. The side
chains of Cys197 and Cys121 form a disulfide bridge within the NPS-binding site.
doi:10.1371/journal.pone.0029523.g005
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As shown in Table 2, where the results obtained from the analysis
of the remaining SNPs are reported, we detected significant
association with reduced risk of IBD for the functional haplotype
rs2530547C-rs324981A-rs727162C (OR=0.78; P = 0.0097),
which is composed by alleles corresponding to increased NPSR1
mRNA expression (-103C) and weaker intracellular signalling
(107Asn and 241Ser) at the respective polymorphic positions. The
association signal was almost entirely due to a decreased frequency
of the rs2530547C-rs324981A-rs727162C haplotype among UC
patients (OR=0.73; P= 0.0059), while a similar trend was
observed among CD patients, although this did not reach
statistical significance (OR=0.83; P= 0.11). No other significant
associations were detected in this relatively small sample set,
including when the functional SNPs were individually tested (not
shown).
Discussion
We report here a thorough characterization of NPSR1
polymorphisms potentially affecting neuropeptide S receptor
expression and function. Based on genotyping and sequencing
data publicly available from the International HapMap Project,
we selected and included in our study all NPSR1 promoter and
coding SNPs commonly found in the Caucasian population (minor
allele frequency .0.02). Our data indicate that some of these
polymorphisms impact both the regulation of NPSR1 mRNA
expression and the signalling properties of the corresponding
receptor.
We identified a region upstream the NPSR1 coding sequence
that is able to drive transcription in the only cell line, Colo205,
where NPSR1 mRNA expression has been detected so far.
Predicted binding sites for several transcription factors involved
in neuronal and inflammatory responses map within this region,
and we therefore propose this DNA sequence as the promoter, or
at least one of the promoters, controlling transcription from the
NPSR1 locus. One of the NPSR1 promoter SNPs, rs2530547
(2103), was associated with allelic effects on transcriptional
activity, both in in vitro luciferase assays and in peripheral blood
leukocytes from healthy volunteers, and may therefore be relevant
to disease pathogenesis. Interestingly, the rs2530547 minor allele
T is predicted to abolish a consensus binding site for the
transcription factor ELK1 (Ets domain-containing protein Elk-1).
ELK1 is a nuclear target for the mitogen-activated protein kinase
(MAPK) signalling cascade, which is pro-inflammatory and is also
induced upon NPS-NPSR1 signalling,[4,39] and ELK1 thus
represent an excellent candidate for further investigation on the
regulation of NPSR1 expression.
Only the Ile107Asn coding SNP (rs324981) has been studied in
the past for its functional impact on NPSR1 receptor proper-
ties.[4,37,40] Here, we characterized also the non-synonymous
polymorphisms Cys197Phe (rs34705969), Arg241Ser (rs727162)
and Gln344Arg (rs6972158) for their effect on NPSR1 in terms of
membrane expression, transcriptome changes downstream of NPS
signalling, pharmacological activity, and predicted structural
properties of the receptor (rs34705969). Our data confirm
previous findings on the Ile107Asn variation, with Ile associated
with higher expression on the cell membrane, stronger intracel-
lular cAMP signalling, and more potent induction of gene
transcription changes compared to Asn. However, the results
reported here also indicate that two other coding SNPs, namely
Cys197Phe and Arg241Ser, have important functional effects on
the NPSR1 receptor. Particularly impressive is the loss-of-function
phenotype displayed by the substitution of Cys with Phe at residue
197 (Cys197Phe). Although retaining membrane expression, this
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receptor variant is not able to induce downstream gene expression
changes or cAMP-mediated signalling upon NPS stimulation, even
at high concentrations of ligand. As highlighted by our molecular
model of NPSR1, this is possibly due to the disruption of a
disulfide bridge between Cys192 and Cys197 when the latter is
replaced by Phe. It should be noted that this cysteine bridge, also
present in the crystal structure of bovine rhodopsin, is a highly
conserved feature among GPCRs.[41] In the light of these
findings, it will be important to test whether subjects carrying both
copies of NPSR1 with Phe at residue 197 (SNP rs34705969 TT
homozygotes) possess phenotypic features similar to those
observed in Npsr1 knockout mice, which are viable but show
abnormal responses to stress and increased anxiety-like behav-
iours.[42] Though, the identification of such subjects may be
difficult because of the rarity of this variant. Although not as
dramatic as for SNPs at amino acids 107 and 197, important
functional effects are also seen for the rs727162 coding
polymorphism, which corresponds to an amino acid change from
Arg to Ser at position 241 (Arg241Ser). In our experimental
settings, the presence of a Ser at this position associates with
diminished NPS-induced signalling, as seen both at the level of
transcriptional changes in downstream target genes, and in the
magnitude of the activation of cAMP-dependent luciferase
expression. In our molecular model of NPSR1, the side chain of
residue 241 faces the cytoplasm, and a consensus site for PKA and
PKC phosphorylation is predicted only when a serine is present in
this position. It is known that GPCR phosphorylation can induce
receptor desensitization and attenuation of signalling, and these
bioinformatic predictions are thus in accordance with the reduced
activation of NPSR1 signalling for the 241Ser variant.
Although sometimes with contradictory results, numerous
studies have associated NPSR1 polymorphisms with human
conditions such as asthma and related traits, IBD, functional
gastrointestinal disorders, rheumatoid arthritis, and panic disor-
ders.[11,12,14–27] However, neither the true causative variations,
nor the functional mechanisms responsible for their effect on
disease risk, have been conclusively identified in any of these
studies, and most of the reported associations are with tag SNPs,
intronic markers, or their haplotypic combinations. The large
NPSR1 gene spans 220 kb of DNA sequence on chromosome 7p,
with more than 1000 SNPs and several LD blocks identified in
different populations, and this has hampered the identification of
risk alleles at this locus. The results reported here suggest that
there are at least 4 functional SNPs in the NPSR1 gene, and
previous investigations may therefore need to be re-evaluated in
the light of this finding. In particular, it seems correct to assume
that testing associations with individual NPSR1 SNPs may not be
sufficiently informative, since a higher number of polymorphisms
ultimately determine receptor properties and/or expression levels
(figure 6). These polymorphisms likely exert different effects on
disease risk depending on their respective combinations in cis and,
since promoter and coding functional SNPs do not map within the
same LD block in the NPSR1 gene (figure S4), true risk
combinations may need to be sought irrespective of the LD
structure at the NPSR1 locus. Although not all NPSR1 haplotypes
could be adequately tested because of low allelic frequencies, our
preliminary analysis of ‘‘functional haplotypes’’ in a limited
number of IBD patients and controls appears to support this
hypothesis. First, we detected all possible combinations of alleles at
the tested SNPs (23 = 8 haplotypes), confirming that these
polymorphisms are not in strong LD. Second, although modest,
both the strength of the association (P= 0.0059) and the
magnitude of the risk effect (OR=0.73) observed for the
haplotype rs2530547C-rs324981A-rs727162C in UC are compa-
rable with those detected in much larger studies previously
performed on several thousands individuals. The rs2530547C-
rs324981A-rs727162C protective haplotype should correspond to
a highly expressed (2103C) NPSR1 protein characterized by
reduced signalling properties (107Asn and 241Ser), which is an
intriguing observation requiring mechanistic explanation. This is
unless the protective effect is mediated in heterozygosity with high-
signalling NPSR1 receptor variants, a hypothesis we did not have
enough statistical power to test.
With the limitation that only Caucasian common NPSR1
variants have been functionally tested, this study takes us a step
closer to understanding how genetic variability at the correspond-
ing locus impact human disease, and pave the way to future studies
on larger cohorts of cases and controls. Moreover, additional
NPSR1 rare variants have been recently discovered within the
frame of the 1000 Genome Project Consortium,[43] and similar to
the SNP rs34705969 (Cys197Phe) which shows dramatic func-
tional effects, have never been tested for association in human
diseases. Because of the pleiotropic nature of the NPS-NPSR1
system in immune, endocrine and neurological functions, it cannot
be excluded that NPSR1 functional polymorphisms may have
different risk effects in different disorders.
Finally, the NPS-NPSR1 system holds great potential for
therapeutic exploitation of several diseases when full information
on its biological role is available, and the results reported here may
also be of pharmacogenetic relevance. A number of NPS agonists
and antagonists has already been identified,[44–48] and allele-
specific potency of NPSR1 activation already shown for some NPS
mutant peptides, depending on the residue present at the
polymorphic sites Ile107Asn.[40] It will now be important to
verify whether the differences observed here for some NPSR1
coding SNPs are also conserved when NPS agonists or antagonists
Figure 6. Functional variability in NPSR1 receptor signalling. Based on the results obtained in this study, allelic differences in mRNA
expression and protein signalling capacity exist, respectively, at SNPs corresponding to promoter position 2103 and amino acid residues 107, 197
and 241. This is graphically represented by vertical arrows in the figure, where more arrows indicate higher expression or stronger signalling,
respectively, for promoter and coding SNPs. In theory, this results in 16 potential cis combinations of NPSR1 functional alleles into haplotypes, and
136 different pairs of such haplotypes from 2 chromosomes, establishing a very large gradient of NPSR1 functional variation ranging from low/absent
to very high signalling.
doi:10.1371/journal.pone.0029523.g006
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are used instead of the natural ligand. If so, it is congruous to
predict that a NPS agonist- or antagonist-based therapy would
inevitably fail in homozygous carriers of a Phe at the Cys197Phe
polymorphic site.
Supporting Information
Figure S1 Characterization of NPSR1 predicted pro-
moter. Left: ARTS-predicted NPSR1 promoter sequence,
spanning nucleotides -595 to +1 from the translational start site
(ATG). Transcription factors (TFs) predicted to bind to the
promoter from MatInspector analysis are also reported, with their
recognitions sites underlined. Among these, TFs involved in the
modulation of inflammatory responses are shown in blue, while
TFs known to regulate neurological functions are shown in green.
Four common (MAF.0.02) SNPs mapping within the predicted
promoter region are reported in red, together with the
corresponding alleles at each site. Right: assessment of the
functional activity of NPSR1 predicted promoter in luciferase
reporter assays. Colo205 cells were transiently transfected with
either a promoterless luciferase vector (pGL3-basic) or the same
vector carrying NPSR1 promoter driving luciferase transcription
(pNPSR1P). Results, which are representative of 3 independent
experiments performed in duplicate, are expressed as fold
induction, relative to the luciferase activity obtained for the
control transfection (empty vector).
(TIF)
Figure S2 Gene Ontology (GO) analysis of genes
differentially expressed upon NPS/NPSR1 signaling.
Biological process annotations of the hits identified through
microarray analysis of NPS-induced changes in gene expression,
in HEK293 cells transiently transfected with NPSR1 expression
plasmid vs cells transfected with empty vector.
(TIF)
Figure S3 Characteristics of NPSR1 coding polymor-
phisms. Left: alignment of NPSR1 coding SNPs 107 (rs324981),
197 (rs34705969), 241 (rs727162) and 344 (rs6972158) in different
species. Only residue 344 shows some variability, while residues
107, 197 and 241 are conserved across all species. Right:
Bioinformatic prediction of protein kinase A (PKA) and protein
kinase C (PKC) phosphorylation sites in the region surrounding
the coding SNP 241 (rs727162). Reported is the output of
NetPhosK analysis when a Serine is present at the polymorphic
residue 241. Letter size corresponds proportionally to the score
values obtained from the analysis (PKA=A=0.57; PKC=
C=0.61, at position 241). No phosphorylation is predicted to
occur when an Arginine is present at residue 241 (only Serine (S),
Threonine (T) and Tyrosine (Y) are substrate for PKA and PKC
phosphorylation).
(TIF)
Figure S4 Linkage disequilibrium (LD) structure of the
NPSR1 gene region. LD displayed by GOLD heatmap in the
NPSR1 gene region (chr7:34662000–34887000), generated with
Haploview on genotype data from the CEU (CEPH) population of
European descent. NPSR1 exons (vertical blocks) and the
functional SNPs identified in our study are reported on top of
the LD plot.
(TIF)
Table S1 NPS-inducd differential gene expression in
cells transfected with the indicated NPSR1 variant vs
cells transfected with an empty vector. Genes/probesets
with fold change .2 in at least one transfection are reported
(- denotes downregulation). Fold change values ,2 are reported
only for comparison, and are highlighted in italics.
(PDF)
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